Novacyt S.A.: Launch of PCR Genotyping Assay Portfolio to Detect COVID-19 Variants Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt", the "Company" or the "Group"), an international specialist in clinical diagnostics, announces the launch of a new and innovative portfolio of assays (under the brand name SNPsig ) to aid the diagnosis of the new variants of SARS-CoV-2. Novacyt's existing polymerase chain reaction (PCR) COVID-19 portfolio remains highly accurate in detecting all published SARS-CoV-2 variants. The launch of the new SNPsig portfolio complements and expands the Company's offering into the rapidly evolving requirement for PCR genotyping of variants. As noted by the US Centers for Disease Control and Prevention, multiple SARS-CoV-2 variants emerged in late 2020. The three most notable variants were originally identified by their reporting origin, the UK (20I/501Y.V1 or B.1.1.7), South Africa (20H/501Y.V2 or B.1.351) and Brazil (20J/501Y.V3 or B.1.1.28) but are now prevalent globally